Akero Therapeutics is a clinical-stage company developing transformational therapies for people with metabolic dysfunction-associated steatohepatitis (MASH). Akero Therapeutics Announces …

2 days ago · On Monday, Akero Therapeutics, Inc. (NASDAQ:AKRO) released preliminary topline week 96 results from SYMMETRY Phase 2b study evaluating the efficacy and safety of its …

3 days ago · Akero also presented results from the smaller group of study participants who had liver biopsy results both at baseline and at week 96. (Some people in the trial discontinued due …

3 days ago · Akero Therapeutics has hit a home run, reporting statistically significant results in two key 96-week metabolic dysfunction-associated steatohepatitis (MASH) analyses to send …

1 day ago · Akero Therapeutics announced a public offering of over 5.3 million shares at $48 each, aiming for $350 million in proceeds. Quiver AI Summary. Akero Therapeutics, Inc. has …

Find the latest Akero Therapeutics, Inc. (AKRO) stock quote, history, news and other vital information to help you with your stock trading and investing.

Akero's lead drug candidate, efruxifermin (EFX) has been engineered to mimic the biological activity of FGF21, which regulates multiple metabolic pathways. Akero Therapeutics …

Akero is conducting multiple clinical trials to evaluate an investigational drug, efruxifermin (EFX), as a treatment for MASH. Akero Therapeutics Announces Week 96 Results from Phase 2b …

Mar 4, 2024 · Akero Therapeutics is a clinical-stage company developing transformational treatments for patients with serious metabolic diseases marked by high unmet medical need, …

Sep 13, 2022 · Akero's lead product candidate, efruxifermin (EFX), is a differentiated Fc-FGF21 fusion protein that has been engineered to mimic the balanced biological activity profile of …